Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Site 705, Bracken Ridge, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

sitting office diastolic blood pressure between 90 and 109 mmHg
office systolic blood pressure between 140 and 179 mmHg
mean day-time diastolic 24-h ABPM blood pressure >= 85 mmHg inclusive at baseline

Exclusion criteria

known secondary hypertension
decompensated congestive heart failure

Treatment and study plan

Daglutril

Drug

Sponsors and collaborators

Lead sponsor

Solvay Pharmaceuticals

Industry

Registry information

Official study title

A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension

Important dates

Study start: 2004
First posted: Sep 12, 2005
Registry last updated: Jan 30, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed